-
Innovation Ranking
NewInnovation Ranking – Oncternal Therapeutics
Oncternal Therapeutics (Oncternal), formerly GTx Inc, is a biopharmaceutical company that discovers, develops, and commercializes novel targeted hormonal therapies. It develops small molecules that target hormone pathways for the treatment of various cancers, including breast and prostate cancer and other serious medical conditions. The company’s has pipeline program includes cirmtuzumab, a humanized monoclonal antibody for the treatment of chronic lymphocytic leukemia, metastatic breast cancer and and mantle cell lymphoma; TK216 for treatment of Ewing sarcoma, prostate cancer and acute myeloid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ONCT-808 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONCT-808 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ONCT-808 in B-Cell Non-Hodgkin Lymphoma Drug Details: ONCT-808 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zilovertamab in Nodal Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zilovertamab in Nodal Marginal Zone B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab in Nodal Marginal Zone B-Cell Lymphoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zilovertamab in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zilovertamab in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab in Extranodal Marginal...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Zilovertamab in Splenic Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zilovertamab in Splenic Marginal Zone B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab in Splenic Marginal Zone B-Cell Lymphoma Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Zilovertamab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zilovertamab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab in Triple-Negative Breast Cancer (TNBC) Drug Details: Zilovertamab (UC-961)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zilovertamab in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zilovertamab in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab in Chronic Lymphocytic Leukemia (CLL) Drug Details: Zilovertamab (UC-961)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ONCT-808 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONCT-808 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ONCT-808 in Diffuse Large B-Cell Lymphoma Drug Details: ONCT-808 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ONCT-808 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONCT-808 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ONCT-808 in Mantle Cell Lymphoma Drug Details: ONCT-808 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ONCT-808 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONCT-808 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ONCT-808 in Follicular Lymphoma Drug Details: ONCT-808 is under development for the treatment...